On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

10x Genomics, Inc., a life science technology ... The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...